Healthcare Conference

Teva Pharmaceutical Industries will unveil its “Pivot to Growth” strategy and financial outlook through 2030 at the J.P. Morgan Healthcare Conference. The company aims to transform into a leading biopharmaceutical entity, leveraging its generics business and innovative pipeline.

For 2025, Teva projects revenues of $16.8–$17.0 billion, with substantial free cash flow and EBITDA targets. Looking ahead, it aims for mid-single-digit revenue CAGR by 2030 and over $3.5 billion in free cash flow, alongside reduced net leverage and an investment-grade credit rating. While near-term revenue may be flat, the strategy emphasizes pipeline advancement and financial discipline.

GE HealthCare’s CFO, Jay Saccaro, will present at the Jefferies Global Healthcare Conference on November 18, 2025. The presentation will cover GE HealthCare’s business strategy and growth opportunities amidst evolving healthcare market dynamics. Saccaro is expected to address the impact of a competitor’s FDA approval and reassure investors about GE HealthCare’s competitive position. He will likely highlight the company’s strengths, including global presence, diverse portfolio, and investments in AI and cloud technologies. A live webcast will be available on the GE HealthCare investor relations website.

Quest Diagnostics’ Chairman, CEO, and President, Jim Davis, will speak at the Baird 2025 Global Healthcare Conference on September 10, 2025. He will discuss the company’s strategy, performance, and healthcare market trends. A live webcast of the presentation will be available on the Quest Diagnostics investor relations website, with a replay archived for later viewing. Quest Diagnostics aims to improve health outcomes through its extensive diagnostic testing and insights, serving a large segment of the U.S. population.